Community Health Center Drug Pricing Protection Act
Bill bars Federally-qualified health centers from paying above 340B ceiling prices for drugs, securing program discounts to lower medication costs for low-income patients.
Bill bars Federally-qualified health centers from paying above 340B ceiling prices for drugs, securing program discounts to lower medication costs for low-income patients.
HR 7391 amends the Public Health Service Act to prevent Federally-qualified health centers (FQHCs) from being charged prices higher than the 340B ceiling price when purchasing covered outpatient drugs. The 340B program is a federal discount program that requires pharmaceutical manufacturers to provide significant discounts on medications to eligible healthcare entities. This bill specifically protects FQHCs from paying above-ceiling prices at the point of purchase.
FQHCs serve uninsured, underinsured, and low-income patients across rural and urban areas. Drug pricing directly affects the affordability of care these centers can provide and their operational sustainability. By locking in ceiling prices at purchase, the bill aims to ensure FQHCs receive the full intended benefit of the 340B program, potentially reducing medication costs for vulnerable patient populations and preventing middlemen from capturing program savings.
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.